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Study question: Is a low (<1.0µg/L) or moderately low (1.0−1.9µg/L) serum anti-Müllerian hormone 26 
(AMH) level a risk factor for early pregnancy loss in IVF/ICSI with a fresh or frozen-thawed embryo 27 
transfer (ET)? 28 
Summary answer: A low or moderately low serum AMH level does not associate with miscarriage, 29 
non-visualized pregnancy loss, or overall early pregnancy loss rate in the IVF/ICSI treatment.  30 
What is known already: Low AMH predicts poor ovarian response and small oocyte yield in the 31 
IVF/ICSI treatment, but its value in the evaluation of live birth rate (LBR) is modest. Little is known 32 
about the risk of early pregnancy loss in ART among women with low AMH.  33 
Study design, size, duration: A retrospective cohort study on 1383 women undergoing their first 34 
oocyte retrieval for IVF/ICSI in Helsinki University Hospital in Helsinki, Finland, between 2012 and 35 
2016, with all connected fresh (n=1315) and frozen-thawed (n=1418) ET cycles finished by August 36 
2018. AMH was measured within twelve months before the IVF/ICSI stimulation.  37 
Participants/materials, setting, methods: Of all women, 235 (17.0%) had low (<1.0µg/L), 278 38 
(20.1%) had moderately low (1.0–1.9µg/L) and 870 (62.9%) had normal (≥2.0µg/L) AMH. The 39 
primary outcomes were miscarriage, non-visualized pregnancy loss, and early pregnancy loss 40 
(miscarriage and non-visualized pregnancy loss combined) after fresh or frozen-thawed ET. The 41 
impact of AMH on these outcomes was calculated in three populations: among all women who 42 
became pregnant, among women with AMH ≤6.0µg/L and in a population weighted by the inverse 43 
probability of becoming pregnant (inverse probability weighting, IPW). The impact of AMH was 44 
also assessed on the secondary outcomes, cumulative pregnancy rate (cPR), and cumulative live birth 45 
rate (cLBR) across all ET cycles in the woman’s first IVF/ICSI. Potential confounders (the woman’s 46 
age, overweight, smoking, history of endometriosis, and underlying medical conditions) adjusted the 47 
final results.  48 
Main results and the role of chance: Of 1123 pregnancies, 285 (25.4%) ended in non-visualized 49 
pregnancy loss and 143 (12.7%) in miscarriage. The LBR was 24.6% per ET (673/2733). Low or 50 
moderately low AMH, compared with normal AMH, did not associate with miscarriage or non-51 
visualized pregnancy loss in analyses among all women who became pregnant (adjusted RR for 52 
miscarriage vs. live birth 0.70, 95% CI 0.42–1.17 in low AMH and 1.00, 95% CI 0.68−1.49 in 53 
moderately low AMH; adjusted RR for non-visualized pregnancy loss vs. live birth 0.90, 95% CI 54 
0.65−1.23 in low AMH and 1.09, 95% CI 0.85−1.41 in moderately low AMH), nor did low or 55 
moderately low AMH associate with the overall early pregnancy loss rate (adjusted RR for early 56 
pregnancy loss vs. live birth 0.86, 95% CI 0.68–1.10 in low AMH and 1.01, 95% CI 0.86–1.27 in 57 
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moderately low AMH). Results remained similar after restricting the analysis to women with AMH 58 
≤6.0 ug/L. The women with low or moderately low AMH had fewer pregnancies and live births than 59 
the women with normal AMH in their first IVF/ICSI (cPR/cLBR in the women with low AMH 60 
50.6/34.0%, moderately low AMH 59.0/36.3% and normal AMH 68.3/49.2%). When the lower 61 
probability for pregnancy was considered by using IPW, the women with low or moderately low 62 
AMH did not have a higher risk for miscarriage, non-visualized pregnancy loss, or overall early 63 
pregnancy loss compared to women with normal AMH. 64 
Limitations, reasons for caution: The number of miscarriages in women with low AMH was 65 
moderately small, limiting the power of the study. The real-world clinical setting of the study 66 
restricted the ability to control for all factors causing selection bias.  67 
Wider implications of the findings: The cLBR was higher among women with normal AMH than 68 
among women with low or moderately low AMH in their first IVF/ICSI treatment because these 69 
women had more oocytes and embryos. Women with low or moderately low AMH did not have an 70 
increased risk for early pregnancy loss. This information is reassuring for couples and useful in 71 
counseling. These results are also valuable when assessing the overall effectiveness of IVF/ICSI 72 
treatment.  73 
Study funding/competing interest(s): The research funds from Helsinki University Hospital (No. 74 
TYH2018232), Hyvinkää Hospital (No. M3080TUT18) and the Emil Aaltonen Foundation for P.P., 75 
the grants from the Paulo Foundation and the Finnish Medical Foundation for H.H.. The authors 76 
report no conflicts of interest. 77 
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Today, for various reasons, many women delay childbearing. As women age, their fecundity 88 
decreases, and the risk for miscarriage increases (Menken et al., 1986; Magnus et al., 2019). Such an 89 
age-related increase in the miscarriage rate has been reported in assisted reproduction as well (Farr et 90 
al., 2007). About 20% of IVF pregnancies end in a pregnancy loss, and half of the losses are 91 
biochemical (Farr et al., 2007).  92 
 93 
Advanced age associates with a diminished number and quality of the remaining oocytes, described 94 
as ovarian reserve. There is, however, individual variation in the size of ovarian follicle pool at birth 95 
and rate of its decline thereafter (te Velde and Pearson, 2002). Genes largely explain this variability, 96 
but other factors, such as ovarian surgery, endometriosis, cancer treatments, smoking, and infections, 97 
may also have an impact. Whether the quantitative decrease in the oocytes, independent of the 98 
women’s age, associates with poor oocyte quality as well, has been widely discussed (Broekmans et 99 
al., 2006; Zamah and Stephenson, 2018).  100 
 101 
Anti-Müllerian hormone (AMH) predicts the ovarian response and the oocyte yield in ovarian 102 
stimulation (La Marca et al., 2010), but studies have shown a limited value of AMH to predict live 103 
birth rate (LBR) (Broer et al., 2013; Iliodromiti et al. 2014). These studies have rarely reported on 104 
early pregnancy loss rate, although it might reflect the oocyte quality better than the LBR does. Early 105 
pregnancy loss is often a result of fetal aneuploidy (Hassold and Hunt, 2001), but research on other 106 
etiologies is much needed. Low AMH level as an etiological factor has been suggested, but literature 107 
on this subject, especially regarding ART, is sparse.  The few previous works in this area have studied 108 
miscarriage only after IVF/ICSI fresh embryo transfer (ET) (Tarasconi et al., 2017), whereas taking 109 
the outcome of the whole IVF/ICSI treatment into consideration is what in real life matters to the 110 
couples as well as the clinicians taking care of them.  111 
 112 
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Therefore, our study aimed to clarify the impact of low AMH on the risk of early pregnancy loss and 113 
overall pregnancy outcome in the woman’s first IVF/ICSI treatment. As pregnancy loss is possible 114 
only after becoming pregnant, we considered the lower probability of pregnancy in women with low 115 
AMH in our analyses. Finally, we aimed to deepen the understanding of AMH as a potential 116 
biomarker of the oocyte quality. 117 
 118 
 119 
Materials and Methods 120 
 121 
Study population and design 122 
The study population comprised of women who underwent their first oocyte retrieval for IVF or ICSI 123 
treatment in the Reproductive Medicine Unit of Helsinki University Hospital (Helsinki, Finland) 124 
between January 1st, 2012 and December 31st, 2016. Figure 1 shows the flowchart of participant 125 
selection and an overview of the treatment. We included women who had their serum AMH measured 126 
within the preceding twelve months of their ovarian stimulation and who had had at least one 127 
subsequent ET cycle (fresh or frozen-thawed). The exclusion criteria included treatment with 128 
preimplantation genetic testing or for fertility preservation. Couples’ own gametes were used in all 129 
treatment cycles. We compared the early pregnancy loss rates, including the miscarriage rates and 130 
the non-visualized pregnancy loss rates, between the women with low (<1.0µg/L), moderately low 131 
(1.0−1.9µg/L) and normal (≥2.0µg/L) AMH and calculated the cumulative pregnancy rates (cPRs) 132 
and the cumulative live birth rates (cLBRs). 133 
 134 
The data were collected from medical databases. The baseline characteristics were the woman’s age 135 
at the oocyte retrieval, AMH, BMI, smoking history, the woman’s underlying medical conditions, 136 
previous pregnancies, previous ovarian surgeries, and the diagnosis, the duration and the type 137 
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(primary vs. secondary) of the infertility. The treatment characteristics included the stimulation 138 
protocol (GnRH agonist or antagonist), the total gonadotropin dose, the number of retrieved, mature 139 
and fertilized oocytes, the treatment type (IVF or ICSI) and the number of frozen embryos. The data 140 
on each separate ET cycle included the number of transferred embryos, the cycle type (fresh or frozen-141 
thawed ET), the pregnancy test result, and the pregnancy outcome. The analysis included the 142 
subsequent frozen-thawed embryo transfers (FETs) before August 31st, 2018. 143 
 144 
AMH measurement 145 
The laboratory quantified AMH with an ELISA assay (AMH Gen II ELISA, Beckman Coulter, Brea, 146 
CA, USA). The limit of detection (LoD) was 0.08µg/L, and the limit of quantitation (LoQ) 0.16 µg/L. 147 
The intra-assay and inter-assay coefficient of the variation (CV%) was <6% in the range of 148 
3.8−16.5µg/L. The total CV% was <8%. The statistical analyses used AMH value of 0.1µg/L for 149 
those women who had their AMH level below the limit of quantification (n=28). 150 
 151 
Treatment protocol 152 
The women underwent ovarian stimulation by either the long agonist (midluteal GnRH agonist 153 
suppression) or the short antagonist protocol (antagonist administration starting on stimulation day 154 
five or six). The initial dose of recombinant FSH or human menopausal gonadotropin was 100−375 155 
IU/day depending on the woman’s age, BMI, AMH, and antral follicle count. When the diameter of 156 
three or more follicles reached ≥17mm, the women received a 250µg recombinant hCG or 5000IU 157 
hCG injection subcutaneously, and the oocyte retrieval was scheduled for 36−40 hours later. One 158 
embryo was transferred 2−5 days after the oocyte retrieval. Vaginal micronized progesterone initiated 159 
on the third day after the oocyte retrieval, and it continued on for 12 days. In the cases of possible 160 
severe ovarian hyperstimulation syndrome, all embryos were frozen. The frozen-thawed embryos 161 
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were transferred as single ETs either in a natural cycle with luteal support or in a hormonal 162 
substitution cycle (oral estradiol valerate 4–8mg/day and vaginal progesterone 600mg/day).  163 
 164 
Pregnancy assessment 165 
Pregnancy was detected either by a serum hCG concentration >5.3IU/L 10–12 days after the ET 166 
(n=2655) or by a positive urine hCG test 14 days after the ET (n=78). An intrauterine gestational sac 167 
on the ultrasound examination five weeks after the ET confirmed the clinical pregnancy. The 168 
pregnancy losses were classified according to the European Society of Human Reproduction and 169 
Embryology’s (ESHRE) early pregnancy special interest group’s consensus statement (Kolte et al., 170 
2015). The definition of a miscarriage is the spontaneous demise of an ultrasonically confirmed 171 
intrauterine pregnancy before viability. Non-visualized pregnancy loss, which comprises of 172 
biochemical pregnancies and pregnancies of unknown location (PULs), is defined as decreasing 173 
serum or urinary hCG without the ultrasonic confirmation of the pregnancy. Here, the definition of 174 
early pregnancy loss includes the miscarriages and the non-visualized pregnancy losses; we excluded 175 
the ectopic pregnancies from the pregnancy loss analyses because of their different etiology.  176 
 177 
We diagnosed miscarriages ultrasonically as an intrauterine gestational sac and absent fetal 178 
heartbeats. When a woman had a low serum hCG concentration (<20.0IU/L) 10 – 12 days after ET, 179 
or symptoms of pregnancy loss, serum hCG was measured once a week.  When the pregnancy was 180 
diagnosed only by serum or urine hCG, and the serial measurements of hCG decreased to negative, 181 
a biochemical pregnancy was diagnosed. When the ultrasound examination, histology, or surgery 182 
failed to confirm the location of the pregnancy, a diagnosis of PUL was set.  HCG measurements 183 
continued once a week until hCG was ≤5.3IU/L. Histologic examination was used for differential 184 
diagnosis on demand (e.g., suspected molar or ectopic pregnancy). Live birth was defined as an infant 185 
born alive after 22 gestational weeks.  186 
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Statistical analyses 188 
The differences in the categorial explanatory variables between the women with low (<1.0µg/L), 189 
moderately low (1.0−1.9µg/L) and normal (≥2.0µg/L) AMH were analyzed by the Chi-square test for 190 
independence. The differences in the continuous variables were analyzed by the Kruskal-Wallis test 191 
with a post hoc test of Mann-Whitney U with Bonferroni’s adjustment. The differences in the PRs 192 
per ET and the pregnancy outcomes after a positive pregnancy test between the women with various 193 
AMH levels were analyzed with the Chi-square test. 194 
 195 
The primary outcomes were a miscarriage, non-visualized pregnancy loss, and these variables 196 
combined as early pregnancy loss after a fresh or frozen-thawed ET cycle. To assess the impact of 197 
AMH level on these outcomes, we estimated the relative risk (RR) using the log-binomial regression 198 
among women, who became pregnant (excluding ectopic and terminations of pregnancies). We 199 
calculated RRs in three populations. First, we analyzed all women who became pregnant;  second, 200 
we analyzed women with AMH ≤6.0µg/L to exclude PCOS patients, and third, we used inverse 201 
probability weighting (IPW) to better estimate the pregnancy loss risk among women with low 202 
probability for pregnancy. To account for the repeated ET cycles by individual patients, we performed 203 
modeling with the generalized estimating equation (GEE) analysis  (Missmer et al., 2011; Yland et 204 
al., 2019).  AMH was tested both as a categorical and as a continuous variable. The selection of the 205 
potential confounders was based on a directed acyclic graph (DAG), which describes the relationship 206 
between the exposure (AMH) and the outcome (early pregnancy loss) (Greenland et al., 1999) 207 
(Supplementary Figure S1).  Based on the DAG, the results were adjusted by the woman’s age on the 208 
oocyte retrieval day in the age groups <35, 35−37 and ≥38, smoking during IVF/ICSI (yes/no), 209 
overweight (BMI >25kg/m2) and a diagnosis of endometriosis (yes/no). We adjusted the results also 210 
by those underlying medical conditions, which may influence both AMH and the risk of early 211 
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pregnancy loss, such as diabetes, rheumatic disease, celiac or inflammatory bowel disease, multiple 212 
sclerosis, or a previous cancer treatment (medical condition, yes/no). We were not able to adjust the 213 
results by woman’s ethnic origin, a potential confounder, because no information on it exists in the 214 
medical databases. Since women with PCOS  may be more likely to experience pregnancy loss, we 215 
conducted sub-analyses among women with AMH ≤6.0µg/L. Currently, no consensus exists of an 216 
AMH cutoff value, which discriminates PCOS patients from non-PCOS patients (Teede et al., 2018). 217 
Based on a recent publication in Finnish population (Sova H et al., 2019), we chose the AMH limit 218 
of  >6.0µg/L to exclude PCOS patients. 219 
 220 
Because pregnancy loss is possible only after becoming pregnant, women with low probability for 221 
pregnancy in IVF/ICSI may be underrepresented in the pregnancy loss study population. It is possible 222 
to address this selection bias through weighting the data by inverse probability of pregnancy. IPW is 223 
a method, which is widely used in epidemiological studies (Crowson et al.,2013) and which has been 224 
used in IVF studies as well (Modest et al., 2018). Here, we used IPW to better estimate pregnancy 225 
loss risk among women with low probability for pregnancy, such as women with low or moderately 226 
low AMH. IPW created a pseudopopulation with heavier weight on women, who became pregnant 227 
despite of their low pre-treatment probability for pregnancy and lighter weight on women who had a 228 
high probability of becoming pregnant. 229 
 230 
We used a binary logistic regression to create women’s predictive probability for becoming pregnant 231 
(p) and not becoming pregnant (1-p). As the dependent variable, we used cumulative pregnancy 232 
(whether a woman became pregnant at least once after any ET cycle in the woman’s first IVF/ICSI). 233 
As the independent variables, we used ten baseline covariates: woman’s age at oocyte retrieval, 234 
AMH, primary/secondary infertility, being healthy (yes/no), smoking during IVF, BMI, the total 235 
gonadotropin dose, treatment type (IVF/ICSI), the number of mature oocytes produced by IVF/ICSI 236 
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and the embryo/mature oocyte ratio. We then created stabilized weights for women with cumulative 237 
pregnancy (P/p) and women without cumulative pregnancy [(1-P)/(1-p)], where P was the overall 238 
probability for cumulative pregnancy in the study population. The mean of the stabilized weights was 239 
1,00. We truncated the final weights at 99th percentiles. Stabilized weights were then used in the log-240 
binomial regression analysis with GEE to estimate RRs for miscarriage and non-visualized pregnancy 241 
loss vs. live birth. We restricted this sub-analysis to women with AMH ≤6.0µg/L. The model had 242 
fairly good discrimination between those who became pregnant and those who did not (c-statistics 243 
0.71). As a limitation of the IPW analysis,  the GEE model allowed only a single weight for each 244 
woman. Thus, we were not able to use cycle-specific variables in creating the weights.  245 
 246 
The secondary outcomes were cumulative pregnancy  (at least one positive pregnancy test result in 247 
the woman’s first IVF/ICSI, including all consecutive ETs) and cumulative live birth (at least one 248 
live birth in the woman’s first IVF/ICSI). We calculated the cPR (and the cLBR) in a “conservative” 249 
manner, which assumes that women who did not return to the next ET had a zero probability of live 250 
birth (Maheshwari et al., 2015). We used the number of women with their first pregnancy (first live 251 
birth) after consecutive ETs as a numerator and the number of all women as a denominator. The 252 
impact of AMH on the cumulative pregnancy (vs. no pregnancy) and on the cumulative live birth (vs. 253 
no live birth) in the couple’s first IVF/ICSI were analyzed by using the log-binomial generalized 254 
linear model in all women and in women with AMH ≤6.0µg/L. The results were then adjusted for 255 
age, smoking, overweight, endometriosis, and underlying medical conditions — the selection of 256 
adjusting variables was based on a DAG (Supplementary figure S2). Finally, we stratified the results 257 
by the number of mature oocytes (1-4, 5-9, and ≥10).  258 
 259 
The data were analyzed by using Microsoft’s Statistical Package for Social Sciences (SPSS), version 260 
25.0. A P-value of less than 0.05 was considered statistically significant.  261 
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 262 
Missing data 263 
Data on BMI was missing for five (0.4%,) and smoking for nine (0.6%,) of the 1383 women. The 264 
outcome of one pregnancy remained unknown. Since the number of missing data was few, they were 265 
omitted from the corresponding analyses.  266 
 267 
Ethical approval 268 
This study received research permissions from Helsinki University Hospital and Hyvinkää Hospital; 269 





The study population comprised of 1383 women having their first IVF/ICSI treatment with at least 275 
one ET (fresh or frozen-thawed). The women’s median age was 33.8 years and ranged from 21 to 40 276 
years. AMH ranged from <0.2µg/L to 43.6µg/L. Of all women, 235 (17.0%) had low (<1.0µg/L), 277 
278 (20.1%) had moderately low (1.0−1.9µg/L) and 870 (62.9%) had normal AMH (≥2.0µg/L). The 278 
women with low and moderately low AMH were older than the women with normal AMH, as 279 
presumed (Table I). This led to differences in the IVF/ICSI protocols and outcomes as the women 280 
with low AMH had the highest gonadotropin dose, the smallest number of retrieved, mature and 281 
fertilized oocytes, and frozen embryos (Table II). The mean number of retrieved oocytes were 6.9, 282 
9.5 and 13.4, and the mean number of frozen embryos were 1.4, 1.9 and 3.2 in women with low, 283 
moderately low and normal AMH, respectively. 284 
 285 
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The women underwent 2733 ET cycles (median 2, range 1−11 per woman), of which 1315 were fresh 286 
and 1418 frozen-thawed ETs. A single embryo was transferred in 2719 (99.5%) of all ET cycles. The 287 
PR per ET cycle in the whole study population was 41.1% (40.8% per transferred embryo) and the 288 
clinical PR 30.2% (30.0% per embryo). Of all 1123 pregnancies, 285 (25.4%) ended in a non-289 
visualized pregnancy loss (of which 272 were biochemical pregnancies and 13 PULs), 143 (12.7%) 290 
ended in a miscarriage, 7 (0.6%) in a termination of the pregnancy and 14 (1.2%) were ectopic 291 
pregnancies. The LBR was 24.6% per ET cycle (673/2733) and 23.5% per transferred embryo 292 
(673/2861). The outcome of one pregnancy remained unknow. There were no stillbirths. 293 
 294 
The PRs per ET varied between the women with different AMH levels, but the women with low or 295 
moderately low AMH were not more likely to undergo early pregnancy loss than those with normal 296 
AMH (Figure 2). 297 
 298 
Low or moderately low AMH, compared with normal AMH, did not associate with miscarriage or 299 
non-visualized pregnancy loss, not even after adjusting for age and the other confounders (Table III). 300 
Results remained similar after restricting the analysis to women with AMH  ≤6.0µg/L and considering 301 
the lower probability of pregnancy in women with low AMH by IPW analysis. The women with very 302 
low AMH (<0.5µg/L vs. ≥2.0µg/L) showed no increase in the miscarriage or non-visualized 303 
pregnancy loss risk either (unadjusted RR for miscarriage vs. live birth 0.89, 95% CI 0.40 – 1,94 and 304 
for non-visualized pregnancy loss vs. live birth 1.11, 95% CI 0.68 – 1.70). When AMH was tested as 305 
a continuous variable, the unadjusted RR for miscarriage was 0.99, 95% CI 0.90 – 1.09, and for non-306 
visualized pregnancy loss 0.95, 95% CI 0.88 – 1.02, women with AMH >6.0µg/L omitted. Compared 307 
to women who were  <35 years of age, women aged ≥38 had higher miscarriage risk, and women 308 
aged ≥35 had higher non-visualized pregnancy loss risk. Smoking, overweight, history of 309 
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endometriosis or medical conditions were not associated with miscarriage or non-visualized 310 
pregnancy loss. 311 
 312 
Compared with live birth, neither low nor moderately low AMH increased the risk for early 313 
pregnancy loss (RR 0.86, 95% CI 0.68–1.10 for low and RR 1.01, 95% CI 0.86–1.27 for moderately 314 
low AMH after adjustment for age, smoking, overweight, endometriosis and medical conditions). 315 
The results were similar even though women with AMH >6.0µg/L were omitted from analyses. 316 
 317 
Figure 3 shows the cPRs and the cLBRs across all ETs connected with the first IVF/ICSI in women 318 
with the different AMH levels. The univariable log-binomial regression analysis showed lower RRs 319 
for cumulative pregnancy and cumulative live birth for the women with low or moderately low AMH 320 
when compared with the women with normal AMH (Table IV). Adjustment for age and the other 321 
confounders and the omission of women with AMH >6.0 did not have an impact on the results. 322 
Compared to women <35 years of age, women ≥38 years showed lower cPR and cLBR, whereas 323 
smoking, overweight, endometriosis, or underlying medical conditions showed no effect. After 324 
stratifying the results by the number of mature oocytes, and adjusting by women’s age, the differences 325 
in cPR or cLBR between AMH groups were no more evident, although women with moderately low 326 
AMH and mature oocyte number of ≥10 had lower cPR and cLBRs than women with normal AMH  327 
having the same amount of oocytes (table V). Also, women with 1-4 oocytes and low or moderately 328 
low AMH had a tendency to a lower cLBR compared with women with normal AMH. The proportion 329 
of women who went through their first IVF treatment without becoming pregnant during the follow-330 






This study showed that the women with low (<1.0µg/L) or moderately low (1.0−1.9µg/L) serum 336 
AMH levels had fewer pregnancies than the women with normal AMH (≥2.0µg/L) in their first 337 
IVF/ICSI treatment. When the pregnancy began, however, the women with low or moderately low 338 
AMH did not have an increased early pregnancy loss rate. 339 
 340 
In the light of previous studies, the lack of an association between low AMH and pregnancy loss was 341 
somewhat unexpected. A very similar study design as ours showed an association between low AMH 342 
and an increased miscarriage rate in a population of 1060 IVF-ET cycles, although the difference in 343 
the women younger than 34 years was non-significant (Tarasconi et al., 2017). They included mostly 344 
double ETs and fewer possible confounding variables than we did. They studied miscarriage after 345 
fresh ETs only whereas we also included the subsequent FETs in our analyses. This is what matters 346 
in the clinical practice context and to the infertile couples. Their study population might differ from 347 
ours in the women’s ethnicity, a known factor to influence both AMH (Seifer et al., 2009) and the 348 
miscarriage rate after IVF (Seifer et al., 2008). Additionally, we calculated the risk for early 349 
pregnancy loss in three different populations, with consistent results, which strengthens our findings 350 
of no association between AMH and early pregnancy loss.  351 
 352 
Studies on the AMH level and miscarriage after a natural conception have shown confounding results. 353 
The largest prospective cohort study on 533 women (aged 30 to 44 years, who conceived naturally) 354 
reported that those with very low AMH (≤0.4ng/mL) had an over two-fold increased risk for 355 
miscarriage when compared to the women with AMH ≥1.0ng/mL (Lyttle Schumacher et al., 2018),  356 
while we did not find an increased risk among women with very low AMH (<0,5µg/L). Lyttle 357 
Schumacher’s study population differs markedly from ours since women with infertility, PCOS or 358 
endometriosis were excluded from their study. PCOS and endometriosis are both common reasons 359 
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for infertility and seem to alter ovarian reserve and the odds of a pregnancy loss. Moreover, they 360 
define pregnancy loss differently than we and apply different AMH cut-off levels.  361 
 362 
Some previous studies have suggested recurrent miscarriage to be associated with low AMH. 363 
Atasever et al. (2016) found lower AMH in the women with recurrent miscarriages when compared 364 
with the age-matched general population (2.9ng/mL vs. 3.6ng/mL) and another cohort of 144 women 365 
reported lower AMH in the women with idiopathic recurrent miscarriage when compared with the 366 
women with explained recurrent miscarriage (1.2ng/mL vs. 2.0ng/mL) (Pils et al., 2016). On the other 367 
hand, AMH was not associated with pregnancy loss in the women with one or two previous pregnancy 368 
losses (Zarek et al., 2016), nor did it predict the outcome of further pregnancies in the women with 369 
recurrent miscarriage (Pils et al., 2019). In Zarek’s study, women conceived without ART and 370 
received 400µg folic acid with either placebo or 81mg aspirin with the primary outcome of live birth, 371 
and in Pils’es study, women received combination therapy (aspirin, dydrogesterone, prednisone, and 372 
folic acid)  for the prevention of miscarriage. Study populations in the recurrent pregnancy loss 373 
studies differ from ours, as the women were fertile and younger. In our study, the number of women 374 
with recurrent pregnancy loss was too small for sub-analyses. Hence, our study does not add 375 
knowledge of the role of AMH on recurrent miscarriage. In general, recurrent miscarriage has 376 
multiple etiologies, and the role of AMH remains controversial.   377 
 378 
The strengths of our study are a homogenous population of women undergoing the their first 379 
IVF/ICSI treatment in one university hospital unit with very uniform treatment practices. Well-380 
documented data allowed us to control the results with several confounding factors. The lack of 381 
association between AMH level and early pregnancy loss was shown even after exclusion of women 382 
with high AMH and considering the lower pregnancy rate connected with low or moderately low 383 
AMH by IPW. These sub-analyses are key strengths of our study. The vast majority of the ETs were 384 
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single ETs, which enabled us to identify each embryo’s individual risk for loss, not confounded by 385 
other transferred embryos. We observed not only the fresh ET, but also the entire IVF/ICSI treatment, 386 
including all subsequent FETs, which increased the power of the study, and allowed the calculation 387 
of the cPR and the cLBR. The cumulative live birth rate was higher among women with normal AMH 388 
compared to women with low or moderately low AMH. About half of the women with normal AMH 389 
had at least one child during their first IVF/ICSI treatment, while only one-third of women with low 390 
AMH did. This  finding is useful in everyday practice when clinicians counsel couples before their 391 
first IVF/ICSI treatment. This information is also useful when assessing the overall effectiveness of 392 
the services of an IVF clinic.   393 
 394 
Only a few previous studies have reported associations between AMH and non-visualized pregnancy 395 
loss. An elevated AMH level associated with a biochemical loss in Lyttle Schumacher’s study (2018), 396 
but the number of biochemical losses (n=9) was too small for conclusions. An earlier study reported 397 
a biochemical PR of 13.8% after IVF-ET, which was comparable with the biochemical PR of the 398 
fertile population with natural conceptions (Zeanda et al., 2015). The non-visualized pregnancy loss 399 
rate in our study, including the biochemical pregnancies and the PULs, was high; 25.4% of all 400 
pregnancies. Such a high rate may have two explanations. First, hCG was measured mostly from 401 
serum, a sensitive method to detect even minor elevations. Second, ESHRE’s definition for non-402 
visualized pregnancy loss is broad, including all pregnancies not confirmed by ultrasound, histology, 403 
or surgery, irrespective of the gestational age. Thus, a proportion of the pregnancies, which are in 404 
everyday clinical practice classified as miscarriages, were classified as non-visualized pregnancy 405 
losses in our study.  406 
 407 
The lack of association between low AMH and early pregnancy loss does not support the idea of 408 
AMH as a biomarker for the oocyte quality. Poor oocyte quality is thought to associate with the 409 
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aneuploidy of the oocytes. Although some evidence exists that low AMH might relate to a higher rate 410 
of aneuploid embryos detected by preimplantation genetic testing (Katz-Jaffe et al., 2013), a more 411 
recent report did not find such an association (Morin et al. 2018). We showed lower cPRs and cLBRs 412 
for the women with low or moderately low AMH when compared to those with normal AMH. The 413 
smaller oocyte yield and higher age largely explained these differences, however. Also Li et al. (2013) 414 
found that after adjusting for age and the number of available embryos, AMH was not a significant 415 
predictor for the cLBR in the woman’s first IVF. The results of our study and this previous study 416 
indicate that  women with low or moderately low AMH have a smaller number of retrieved oocytes, 417 
less embryos to select from for the ET, and less ETs, leading to lower cPR and cLBR, but these 418 
women do not have a higher pregnancy loss rate. As a conclusion, AMH seems to be a biomarker of 419 
oocyte quantity rather than oocyte quality. 420 
 421 
Pregnancy loss is conditional upon becoming pregnant, and AMH has an impact on pregnancy rate. 422 
In our study, women with low or moderately low AMH went through their first IVF/ICSI treatment 423 
without having a pregnancy (dropped out) more often than women with normal AMH, which may 424 
cause selection bias because these women were underrepresented in the pregnancy loss study 425 
population. In order to assess the possible selection bias, we used the IPW method and found no 426 
differences in early pregnancy loss risk between AMH levels. Unfortunately, we were not able to 427 
assess the individual reasons (the depletion of the frozen embryos, spontaneous pregnancy, other 428 
personal reasons, or the end of the follow-up period) for stopping the treatment. Our observational 429 
study reflects a real-world setting, where the couple’s preferences as well as the IVF doctor’s clinical 430 
view affect the decision of starting or continuing the IVF/ICSI treatment. Taken together, our results 431 
indicate that if embryo transfer was carried out, the risk of early pregnancy loss was not increased in 432 
women with low or moderately low AMH. 433 
 434 
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Finally, as limitations of our study, we did not have information on women’s ethnicity, which is one 435 
potential confounder affecting both AMH and the miscarriage rate. Since nearly all women were 436 
Finnish, ethnicity should not be a source of residual confounding. AMH was measured within 12 437 
months before the IVF stimulation since AMH is considered rather stable over this time period 438 
(decline of 5,6% per year) (Bentzen J et al., 2013). Furthermore, the same time frame for AMH 439 
assessment was used in a previous study with similar aims (Tarasconi et al., 2017). AMH has less 440 
inter- and intracycle variability than FSH or antral follicle count, and therefore, is the most appropriate 441 
measurement for ovarian reserve. Although the number of miscarriages was limited, especially in the 442 
women with low AMH, our data included many non-visualized pregnancy losses and the combination 443 
of these outcomes increased the power to detect possible associations. Thus, this study is, to the best 444 
of our knowledge, the largest one testing the association between AMH and early pregnancy loss. 445 
However, even after combining miscarriage and non-visualized pregnancy loss, the confidence 446 
intervals for the RRs were quite wide and one might argue that a larger study population is required. 447 
Therefore, research with an even larger number of pregnancy losses would give more information on 448 




The women with low (<1.0µg/L) or moderately low (1.0−1.9µg/L) AMH had fewer pregnancies in 453 
the their first IVF/ICSI treatment than the women with normal AMH (≥2.0µg/L), but a higher age 454 
and smaller number of oocytes mainly explained the differences. When the pregnancy began, the 455 
women with low or moderately low AMH had as a good chance for a live birth as the women with 456 
normal AMH since the pregnancy loss rates were similar. These results suggest that AMH is a 457 
biomarker for the oocyte quantity, not for the oocyte quality. Our results have clinical value on 458 
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Table I The basic characteristics of the women with low, moderately low and normal AMH. 







Number of patients  235 278 870  
Age (years) 36.3 (23.8–40.7)a,b 34.6 (22.4–40.7)a,c 33.1 (21.4–40.8)b,c <0.0001 
BMI (kg/m2) 23.0 (16.6–36.1) 23.1 (16.9–36.6) 22.7 (16.3–37.4) 0.38 
Smoking in general 54/233 (23.2%) 78/278 (28.1%) 188/867 (21.7%) 0.09 
Smoking during IVF/ICSI  11/233 (4.7%) 11/275 (4.0%) 44/866 (5.1%) 0.76 
Healthy  161 (68.5%) 204 (73.4%) 635 (73.0%) 0.36 
One or several previous 
miscarriage(s) 
28 (11.9%) 36 (12.9%) 117 (13.4%) 0.82 
Duration of infertility (years) 3.0 (0.3–15.0) 3.2 (0.9–18.0) 3.3 (0.7–17.0) 0.06 
Primary infertility 154 (65.5%) 174 (62.6%) 586 (67.4%) 0.34 
Main diagnosis 
  Ovulation disorder 
  Tubal factor 
  Male factor 
  Endometriosis 




















Prior ovarian surgery 40 (17.0%) 36 (12.9%) 62 (7.1%) <0.0001 
The continuous variables are presented as medians (range) and analyzed by using the Kruskal-Wallis test. 
The same superscripts show significant differences between the women with different AMH levels in the Mann-Whitney U-test with Bonferroni’s 
adjustment, Pa-c < 0.0001. 
The categorial variables are presented as numbers (percentages within each AMH level) and analyzed by using the χ2  test.  
AMH, anti-Müllerian hormone 
 
 
Table II The characteristics of the ovarian stimulation and the embryo transfer cycles in the women with low, moderately low and normal AMH. 
Characteristics AMH  P-value 
Low  
(<1.0µg/L) 




Number of stimulation cycles 235 278 870  
Stimulation protocol 
  Long agonist  












  IVF 
  ICSI 














Total dose of gonadotropin (IU) 3000 (1250–6600)a,b 2000 (800–5100)a,c 1375 (440–3875)b,c <0.0001 
Number of oocytes retrieved 6 (1–24)a,b 9 (1–32)a,c 12 (1−51)b,c <0.0001 
Number of mature oocytes 5 (1–24)a,b 8 (1–24)a,c 10 (1–45)b,c <0.0001 
Number of fertilized oocytes 3 (1–21)a,b 5 (1–17)a,c 6 (1–30)b,c <0.0001 
Number of frozen embryos 1 (0–15)d,b 1 (0–16)d,b 2 (0–25 )b,c <0.0001 
Women with ≥1 frozen embryos 128 (54.5%) 186 (66.9%) 665 (76.4%) <0.0001 
Total number of embryo transfer cycles  
  Fresh embryo transfer cycles 
  FET, spontaneous cycles with luteal support 














The categorial variables are presented as numbers (percentages within each AMH level) and analyzed by using the χ2  test.  
The continuous variables are presented as medians (range) and analyzed by using the Kruskal-Wallis test. 
The same superscripts show significant differences between the women with different AMH levels in the Mann-Whitney U-test with Bonferroni’s 
adjustment, Pa,b,c <0.0001, Pd=0.006 





Table III The risk of miscarriage and non-visualized pregnancy loss according to woman’s AMH level in three study populations among women 
who became pregnant in their first IVF/ICSI treatment, including all fresh and frozen-thawed embryo transfers. The log-binomial regression 
analysis with the GEE.  
 
 Miscarriage vs. live birth Non-visualized pregnancy loss vs. live birth 
Unadjusted RR 
(95% CI) 
P-value Adjusteda RR 
(95% CI) 
P-value Unadjusted RR 
(95% CI) 





   Normal (≥ 2.0µg/L) Reference Reference Reference Reference 
   Moderately low (1.0−1.9µg/L) 1.08 (0.73 – 1.61) 0.69 1.00 (0.68 – 1.49) 0.99 1.18 (0.91 – 1.52) 0.21 1.09 (0.85 – 1.41) 0.51 
   Low (< 1.0µg/L) 0.88 (0.54 – 1.42) 0.60 0.70 (0.42 – 1.17) 0.17 1.02 (0.74 – 1.40) 0.90 0.90 (0.65 – 1.23) 0.49 
Women with AMH ≤ 6.0µg/L 
AMH 
   Normal (2.0–6.0µg/L) Reference Reference Reference Reference 
   Moderately low (1.0−1.9µg/L) 1.04 (0.69 – 1.55) 0.87 0.99 (0.67 – 1.48) 0.97 1.17 (0.90 – 1.52) 0.25 1.10 (0.85 – 1.43) 0.48 
   Low (< 1.0µg/L) 0.85 (0.52 – 1.38) 0.51 0.69 (0.41 – 1.16) 0.16 1.01 (0.73 – 1.40) 0.94 0.90 (0.65 – 1.24) 0.51 
IPWb, women with AMH ≤ 6.0µg/L 
AMH 
   Normal (2.0–6.0µg/L) Reference Reference Reference Reference 
   Moderately low (1.0−1.9µg/L) 1.18 (0.82 – 1.71) 0.37 1.13 (0.78 – 1.64) 0.51 1.16 (0.90 – 1.50) 0.21 1.09 (0.85 – 1.40) 0.43 
   Low (< 1.0µg/L) 0.88 (0.55 – 1.38) 0.57 0.70 (0.43 – 1.15) 0.16 1.05 (0.79 – 1.41) 0.72 0.89 (0.66 – 1.19) 0.43 
 
AMH, anti-Müllerian hormone; GEE, generalized estimating equation; RR relative risk 
aRRs adjusted for age, smoking, overweight, history of endometriosis and medical conditions (diabetes, rheumatic or celiac disease, inflammatory 
bowel disease, multiple sclerosis, and previous cancer) 
bData weighted by the inverse of the probability of becoming pregnant (IPW), based on the characteristics of the woman and the IVF/ICSI 
treatment. 
 
Table IV The RRs for having at least one pregnancy (cumulative pregnancy) vs. no pregnancy or at least one live birth (cumulative live birth) vs. no live birth in 
the woman’s first IVF/ICSI, including all embryo transfer cycles among all women and women with AMH ≤6.0µg/L according to AMH level. The log-binomial 
regression analysis. 
 
 Cumulative pregnancy Cumulative live birth 
Unadjusted RR 
(95% CI) 
P-value Adjusteda RR 
(95% CI) 
P-value Unadjusted RR 
(95% CI) 
P-value Adjusteda RR 
(95% CI) 
P-value 
All women N=1383 N=1382 
AMH 
   Normal (≥ 2.0µg/L) Reference Reference Reference Reference 
   Moderately low (1.0−1.9µg/L) 0.86 (0.78 – 0.96) 0.008 0.87 (0.78 – 0.97) 0.012 0.74 (0.63 – 0.88) 0.001 0.76 (0.64 – 0.90) 0.002 
   Low (< 1.0µg/L) 0.74 (0.65 – 0.85) <0.001 0.78 (0.68 – 0.89) <0.001 0.70 (0.58 – 0.84) <0.001 0.79 (0.65 – 0.96) 0.02 
Women with AMH ≤6.0µg/L N=1193 N=1192 
AMH 
   Normal (2.0–6.0µg/L) Reference    
   Moderately low (1.0−1.9µg/L) 0.89 (0.80 – 0.99) 0.048  0.90 (0.80 – 1.01) 0.06 0.77 (0.65 – 0.92) 0.003 0.79 (0.66 – 0.94) 0.007 
   Low (< 1.0µg/L) 0.77 (0.67– 0.88) <0.001 0.80 (0.69 – 0.92) 0.002 0.72 (0.59 – 0.88) 0.001 0.81 (0.66 – 0.99) 0.04 
 
AMH, anti-Müllerian hormone; RR, relative risk 
aRRs adjusted for age, smoking, overweight, history of endometriosis and medical conditions (diabetes, rheumatic or celiac disease, inflammatory 
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AMH, anti-Müllerian hormone; RR, relative risk 
aRRs adjusted for age, smoking, overweight, history of endometriosis and medical conditions (diabetes, rheumatic or celiac disease, inflammatory 




Table V The RRs for having at least one pregnancy (cumulative pregnancy) vs. no pregnancy or at least one live birth (cumulative live birth) vs. no live birth in 
the woman’s first IVF/ICSI in women with normal, moderately low and low AMH stratified by the number of mature oocytes. A log-binomial regression analysis, 

























Normal  (2.0–6.0µg/L) Reference  Reference Reference  Reference 
Moderately low (1.0–1.9µg/L) 1.05 (0.74 – 1.50) 0.77 1.04 (0.73 – 1.50) 0.81 0.70 (0.39 – 1.25) 0.28 0.67 (0.38 – 1.17) 0.16 
Low  (<1.0µg/L) 0.91 (0.65 – 1.27) 0.59 0.92 (0.65 – 1.31) 0.63 0.77 (0.48 – 1.25) 0.16 0.78 (0.48 – 1.26) 0.31 
5-9 
(484) 
Normal  Reference  Reference Reference  Reference 
Moderately low  1.08 (0.91 – 1.28) 0.40 1.09 (0.92 – 1.29) 0.34 1.00 (0.77 – 1.30) 0.99 1.02 (0.79 – 1.32) 0.89 
Low  0.93 (0.75 – 1.14) 0.47 0.94 (0.76 – 1.16) 0.54 0.95 (0.71 – 1.28) 0.75 1.01 (0.75 – 1.35) 0.96 
>10 
(463) 
Normal  Reference  Reference Reference  Reference 
Moderately low  0.81 (0.68 – 0.97) 0.02 0.81 (0.68 – 0.96) 0.02 0.75 (0.57 – 0.97) 0.03 0.79 (0.61 – 1.03) 0.08 
Low  0.92 (0.73 – 1.16) 0.40 0.92 (0.73 – 1.16) 0.49 0.97 (0.69 – 1.35) 0.71 1.09 (0.79 – 1.51) 0.57 
AMH, anti-Müllerian hormone; RR, relative risk; CI, confidence interval. 
aRRs adjusted for age, smoking, overweight, history of endometriosis and medical conditions (diabetes, rheumatic or celiac disease, inflammatory bowel 
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AMH, anti-Müllerian hormone; RR, relative risk; CI, confidence interval. 
aRRs adjusted for age, smoking, overweight, history of endometriosis and medical conditions (diabetes, rheumatic or celiac disease, inflammatory bowel 





Figure 1. A flowchart of the patient selection and an overview of the IVF/ICSI treatments with all 
connected fresh and frozen-thawed embryo transfer (ET) cycles with the reproductive outcomes in 
women with low (<1.0μg/L), moderately low (1.0 – 1.9μg/L) and normal (≥2.0μg/L) anti-Müllerian 




Women with their first 
oocyte retrieval  
Jan. 2012 – Dec. 2016 
N=1814 
 
1383 women in the 
final analyses 
 
Excluded from the analyses: 




Fertility preservation N=20 
No mature oocytes N=26 
No fertilized oocytes N=89 
Abnormal development of 
embryos N=41 
No ET for social reasons N=5 
 







Frozen-thawed ETs  
before Sept. 2018 
N=232 ETs 
Positive hCG N=92 
Non-visualized 
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N=116 women  
(49.4% of women with 
low AMH) 
N=114 women  
(41.0% of women with 
moderately low AMH) 
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Figure 2 (A) The unadjusted pregnancy rates (positive pregnancy test per ET cycle) among the women 
with low (<1.0μg/L), moderately low (1.0–1.9μg/L), and normal (≥2.0μg/L) AMH level. (B) The 
unadjusted frequencies of non-visualized pregnancy losses, miscarriages, and live births after a 
positive pregnancy test according to the AMH levels. A Chi-square test showed a relationship between 





































































Figure 3 The unadjusted cumulative pregnancy rates (A) and the unadjusted cumulative live birth rates 
(B) in the women with low (<1.0μg/L), moderately low (1.0 – 1.9μg/L), and normal (≥2.0μg/L) AMH after 
consecutive ET cycles connected with couple’s first IVF/ICSI stimulation.  
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Variable affecting both 
exposure and outcome 
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a Rheumatic, celiac or inflammatory bowel disease, 
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Pregnancy 
or live birth
Gravidity Parity
Other variable
